Browsing Tag
SUBLOCADE
3 posts
Supernus and Indivior complete merger, creating $2.2bn CNS pharma group
Supernus Pharmaceuticals and Indivior Pharmaceuticals have completed their merger, establishing a diversified central nervous system drug company with approximately $2.2 billion in historical pro forma annual revenue. The transaction combines five core growth medicines and targets $125 million in annual cost savings, but a $1 billion special dividend and new debt obligations place financial discipline alongside commercial expansion.
Why addiction treatment companies like Indivior are re-anchoring corporate control in the U.S.
Find out why Indivior’s U.S. redomiciliation signals a broader strategic shift across addiction treatment and regulated healthcare companies.
Indivior (Nasdaq: INDV) study supports 300 mg SUBLOCADE dose for fentanyl-heavy opioid use cases
Indivior’s new trial results highlight how higher-dose SUBLOCADE may better support fentanyl users in OUD treatment. See what this means for the industry.